ERAS logo

Erasca, Inc. (ERAS)

Profile

Full Name

Erasca, Inc.

Ticker

NASDAQ: ERAS

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

July 16, 2021

Indexes

Not included

Website

https://www.erasca.com

Employees

103

Key Details

Price

$3.60(6.51%)

Market Cap

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$0.00(0.00% YoY)

Annual EPS

-$0.69(16.96% YoY)

PE Ratio

-

Next earnings date

Mar 19, 2026

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    See Full Chart & Historical Data

    Analyst ratings

    Price

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Current Price

    $3.60
    ERAS price is $3.60

    30-Day Relative Volume

    0.96
    ERAS 30-day relative volume is 0.96

    Price Performance

    Price Most Recent Change

    +6.51%
    ERAS price was up +6.51% on Dec 12, 2025

    Price YTD Change

    +43.43%
    ERAS price is up +43.43% since January 1st

    Price 1-Year Change

    +36.88%
    ERAS price is up +36.88% year-on-year

    Price 3-Year Change

    -26.98%
    ERAS price is down -26.98% over the past 3 years

    Price Range

    Price All-Time High

    $24.47
    ERAS price is currently -85.29% below its historical high of $24.47

    Price 3-Year Low

    $1.01
    ERAS price is currently +256.44% above its 3-year low

    Capitalization

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Market cap

    Market Cap

    $1.02B
    ERAS market cap is $1.02 billion

    Market Cap 3-Year Change

    +53.84%
    ERAS market cap is up +53.84% over the past 3 years

    Market Cap All-Time High

    $2.95B
    ERAS market cap is currently -65.38% below its historical high of $2.95 billion

    Market Cap Sector Percentile

    70.26%
    ERAS market cap is higher than 70.26% of companies in Healthcare sector

    Shares Outstanding

    Shares Outstanding 1-Year Change

    +0.35%
    ERAS shares outstanding is up +0.35% year-on-year

    Shares Outstanding 3-Year Change

    +110.67%
    ERAS shares outstanding is up +110.67% over the past 3 years

    Technical Indicators

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Beta

    1.27
    ERAS beta is 1.27

    200-day SMA

    $1.77
    ERAS price is currently +103.14% above its 200-day simple moving average

    50-day SMA

    $2.67
    ERAS price is currently +35.00% above its 50-day simple moving average

    14-Day RSI

    71.79
    ERAS 14-day relative strength index is 71.79

    Volume

    0.96
    ERAS 30-day relative volume is 0.96

    ATR

    $0.22
    ERAS average true range is $0.22

    10-day Historical Volatility

    90.50%
    ERAS 10-day historical volatility is 90.50%

    Dividend

    Income Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Revenue

    Revenue

    $0.00
    ERAS annual revenue is $0.00

    Revenue Analysts Estimate

    -
    ERAS annual revenue consensus analysts' forecast is unknown

    Revenue 1-Year Change

    0%
    ERAS annual revenue has remained unchanged year-on-year

    Revenue Sector Percentile

    28.27%
    ERAS annual revenue is higher than 28.27% of companies in Healthcare sector

    EPS

    EPS

    -$0.69
    ERAS annual earnings per share is -$0.69

    EPS Analysts Estimate

    -$0.27
    ERAS annual earnings per share is currently -152.43% lower than the consensus analysts' forecast

    EPS 1-Year Change

    +16.96%
    ERAS annual earnings per share is up +16.96% year-on-year

    EPS Sector Percentile

    63.28%
    ERAS annual earnings per share is higher than 63.28% of companies in Healthcare sector

    Profit

    Gross Profit

    -$3.81M
    ERAS annual gross profit is -$3.81 million

    Gross Margin

    -
    ERAS annual gross profit margin value is unknown

    Operating Profit

    -$157.09M
    ERAS annual operating income is -$157.09 million

    Operating Margin

    -
    ERAS annual operating profit margin value is unknown

    Net Income

    -$161.65M
    ERAS annual net profit is -$161.65 million

    Net Margin

    -
    ERAS annual net profit margin value is unknown

    Expenses

    Total Expenses

    $157.09M
    ERAS annual total expenses is $157.09 million

    Operating Expenses

    $157.09M
    ERAS annual total operating expenses is $157.09 million

    Cost Of Goods Sold

    $3.81M
    ERAS annual cost of goods sold is $3.81 million

    Selling, General & Administrative Expenses

    $41.73M
    ERAS annual SG&A is $41.73 million

    Depreciation & Amortization

    $3.81M
    ERAS annual D&A is $3.81 million

    Interest Expense

    $0.00
    ERAS annual interest expense is $0.00

    Income Tax

    $0.00
    ERAS annual income tax is $0.00

    EBIT & EBITDA

    EBIT

    -$157.09M
    ERAS annual earnings before interest & taxes is -$157.09 million

    EBITDA

    -$153.28M
    ERAS annual EBITDA is -$153.28 million

    Balance Sheet

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Assets

    Total Assets

    $502.53M
    ERAS annual total assets is $502.53 million

    Non Current Assets

    $193.73M
    ERAS annual long term assets is $193.73 million

    Current Assets

    $308.79M
    ERAS annual total current assets is $308.79 million

    Cash and Cash Equivalents

    $67.74M
    ERAS annual cash & cash equivalents is $67.74 million

    Accounts Receivable

    -
    ERAS annual accounts receivable value is unknown

    Inventory

    $0.00
    ERAS annual inventory is $0.00

    Liabilities

    Total Liabilities

    $79.03M
    ERAS annual total liabilities is $79.03 million

    Long Term Liabilities

    $47.63M
    ERAS annual total long term liabilities is $47.63 million

    Current Liabilities

    $31.39M
    ERAS annual current liabilities is $31.39 million

    Accounts Payable

    $468.00K
    ERAS annual accounts payable is $468.00 thousand

    Debt

    Total Debt

    $51.89M
    ERAS annual total debt is $51.89 million

    Total Debt 1-Year Change

    -7.11%
    ERAS annual total debt is down -7.11% year-on-year

    Long Term Debt

    $47.27M
    ERAS annual long term debt is $47.27 million

    Short Term Debt

    $4.62M
    ERAS annual short term debt is $4.62 million

    Equity & Capital

    Shareholders Equity

    $423.50M
    ERAS annual stockholders equity is $423.50 million

    Book Value

    $423.50M
    ERAS annual book value is $423.50 million

    Retained Earnings

    -$767.66M
    ERAS annual retained earnings is -$767.66 million

    Working Capital

    $277.40M
    ERAS annual working capital is $277.40 million

    Cash Flow Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Cashflow Activities

    Cash From Operations

    -$109.42M
    ERAS annual cash from operations is -$109.42 million

    Cash From Operations 1-Year Change

    -8.1%
    ERAS annual cash from operations is down -8.1% year-on-year

    Cash From Investing

    -$156.62M
    ERAS annual cash from investing is -$156.62 million

    Cash From Investing 1-Year Change

    -71.69%
    ERAS annual cash from investing is down -71.69% year-on-year

    Cash From Financing

    $240.70M
    ERAS annual cash from financing is $240.70 million

    Cash From Financing 1-Year Change

    +18486.64%
    ERAS annual cash from financing is up +18486.64% year-on-year

    CAPEX

    CAPEX

    $60.00K
    ERAS annual capital expenditures is $60.00 thousand

    CAPEX 1-Year Change

    -96.62%
    ERAS annual capital expenditures is down -96.62% year-on-year

    Free Cash Flow

    Free Cash Flow

    -$131.98M
    ERAS annual free cash flow is -$131.98 million

    Free Cash Flow 1-Year Change

    -7.31%
    ERAS annual free cash flow is down -7.31% year-on-year

    Profitability Ratios

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Margins

    Gross Margin

    -
    ERAS annual gross profit margin value is unknown

    Operating Margin

    -
    ERAS annual operating profit margin value is unknown

    Net Margin

    -
    ERAS annual net profit margin value is unknown

    ROA & ROE

    ROA

    -36.01%
    ERAS annual return on assets is -36.01%

    ROE

    -43.68%
    ERAS annual return on equity is -43.68%

    Valuation

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    PE Ratio

    PE Ratio

    -
    ERAS price to earnings ratio value is unknown

    PE Ratio Sector Percentile

    -
    ERAS price to earnings ratio is unknown

    PB Ratio

    PB Ratio

    2.94
    ERAS price to book ratio is 2.94

    PB Ratio Sector Percentile

    61%
    ERAS price to book ratio is higher than 61% of companies in Healthcare sector

    PS Ratio

    PS Ratio

    -
    ERAS price to sales ratio value is unknown

    PS Ratio Sector Percentile

    -
    ERAS price to sales ratio is unknown

    Enterprise value

    Enterprise Value

    $781.26M
    ERAS enterprise value is $781.26 million

    Enterprise Value Sector Percentile

    68.6%
    ERAS enterprise value is higher than 68.6% of companies in Healthcare sector

    EV/EBITDA

    EV/EBITDA

    -5.95
    ERAS EV/EBITDA is -5.95

    EV/EBITDA Sector Percentile

    22.45%
    ERAS EV/EBITDA is higher than 22.45% of companies in Healthcare sector

    Financial Health

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Liquidity

    Current Ratio

    9.84
    ERAS annual current ratio is 9.84

    Quick Ratio

    9.84
    ERAS annual quick ratio is 9.84

    Leverage

    Debt To Equity

    0.12
    ERAS annual debt to equity ratio is 0.12

    Interest Coverage Ratio

    -
    ERAS annual interest coverage ratio value is unknown

    Risk & Stability

    F-Score

    -
    ERAS piotroski f-score value is unknown

    Altman Z-Score

    5.25
    ERAS altman z-score is 5.25

    Analyst ratings

    Recent major analysts updates

    Dec 9, 25 Mizuho
    Outperform
    Nov 14, 25 Guggenheim
    Buy
    Oct 16, 25 Stifel
    Buy
    Sep 3, 25 B of A Securities
    Underperform
    Aug 18, 25 Morgan Stanley
    Equal-Weight
    Apr 30, 25 HC Wainwright & Co.
    Buy
    Mar 26, 25 Raymond James
    Outperform
    Mar 21, 25 HC Wainwright & Co.
    Buy
    Mar 21, 25 Goldman Sachs
    Buy
    Jan 7, 25 B of A Securities
    Buy

    Institutional Ownership

    Screeners with ERAS included

    Growing Shares Outstanding
    US stocks
    Stocks with high beta
    Best performing stocks last month
    Most recommended stocks
    Best performing stocks last 3 months
    NASDAQ Dividend Calendar
    Stocks above SMA 50
    Stocks below analysts price target
    Healthcare sector
    • What is the ticker symbol for Erasca, Inc.?
    • Does Erasca, Inc. pay dividends?
    • What sector is Erasca, Inc. in?
    • What industry is Erasca, Inc. in?
    • What country is Erasca, Inc. based in?
    • When did Erasca, Inc. go public?
    • Is Erasca, Inc. in the S&P 500?
    • Is Erasca, Inc. in the NASDAQ 100?
    • Is Erasca, Inc. in the Dow Jones?
    • When was Erasca, Inc.'s last earnings report?
    • When does Erasca, Inc. report earnings?

    What is the ticker symbol for Erasca, Inc.?

    The ticker symbol for Erasca, Inc. is NASDAQ:ERAS

    Does Erasca, Inc. pay dividends?

    No, Erasca, Inc. does not pay dividends

    What sector is Erasca, Inc. in?

    Erasca, Inc. is in the Healthcare sector

    What industry is Erasca, Inc. in?

    Erasca, Inc. is in the Biotechnology industry

    What country is Erasca, Inc. based in?

    Erasca, Inc. is headquartered in United States

    When did Erasca, Inc. go public?

    Erasca, Inc.'s initial public offering (IPO) was on July 16, 2021

    Is Erasca, Inc. in the S&P 500?

    No, Erasca, Inc. is not included in the S&P 500 index

    Is Erasca, Inc. in the NASDAQ 100?

    No, Erasca, Inc. is not included in the NASDAQ 100 index

    Is Erasca, Inc. in the Dow Jones?

    No, Erasca, Inc. is not included in the Dow Jones index

    When was Erasca, Inc.'s last earnings report?

    Erasca, Inc.'s most recent earnings report was on November 12, 2025

    When does Erasca, Inc. report earnings?

    The next expected earnings date for Erasca, Inc. is March 19, 2026
    On this page